You are here

Breast Cancer Drug, EndoTAG-1, Shows Promise in Phase II Trial

Paclitaxel/lipid combo targets blood supply to tumors (May 16)

A phase II study of neoadjuvant EndoTAG-1 (Medigene AG) — a composition of the cytostatic drug paclitaxel combined with neutral and positive lipids — has met its primary efficacy endpoint in patients with HER2-negative high-risk breast cancer. The results were published online in the ASCO 2013 Annual Meeting Proceedings, a supplement of the Journal of Clinical Oncology.

Fifteen patients diagnosed with non-metastatic HER2-negative breast cancer (ECOG status 0/1) were treated with EndoTAG-1 (22 mg/m2) in combination with paclitaxel (70 mg/m2) once weekly for 12 weeks as neoadjuvant therapy. Following EndoTAG-1 therapy, the patients received standard FEC (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2) chemotherapy every 3 weeks and, subsequently, surgery. The study’s primary endpoint was the percent reduction in tumor volume, as estimated by magnetic resonance imaging (MRI), at the end of administration of EndoTAG-1 plus paclitaxel compared with baseline.

Eleven (73%) of 15 patients showed a reduction in tumor volume of 80% or greater at the end of treatment with EndoTAG-1 plus paclitaxel. The median percent reduction in MRI-estimated tumor volume was 90% (P

The best results were observed in patients with triple-negative breast cancer (TNBC) (six of the 15 patients), all of whom showed reductions in tumor volume of 87% to 100%. Treatment in this group resulted in a pCR in five of the six patients.

During therapy, grade-3 hypersensitivity reactions to EndoTAG-1 were observed in four patients; two patients had a grade-3 increase in transaminases; and one patient had grade-4 neutropenia.

According to the drug’s developer (Medigene AG), the positively charged lipids in EndoTAG-1 imply that the drug interacts with newly developed, negatively charged endothelial cells, which are primarily required for the growth of tumor blood vessels. The paclitaxel component of EndoTAG-1 attacks the endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to healthy tissue. By doing this, EndoTAG-1 is expected to prevent the formation of new tumor blood vessels, thereby inhibiting tumor growth.

Source: Medigene AG; May 16, 2013.

Recent Headlines

Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Zip Device Faster to Apply, Minimizes Scarring
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen